In turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions

In turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions

After the FDA rejected and questioned Ardelyx’s potential drug for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis, the FDA’s Cardiovascular and Kidney Drug Advisory Committee voted Wednesday 9-4 in favor of the drug as monotherapy, and 10-2 (with one abstention) in favor of the drug when given in combination with …

In turn, FDA adcomm votes in favor of Ardelyx CKD drug despite agency questions Read More »